Literature DB >> 23068711

Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.

Matthew J Nyflot1, Paul M Harari, Stephen Yip, Scott B Perlman, Robert Jeraj.   

Abstract

UNLABELLED: Spatial organization of tumor phenotype is of great interest to radiotherapy target definition and outcome prediction. We characterized tumor phenotype in patients with cancers of the oropharynx through voxel-based correlation of PET images of metabolism, proliferation, and hypoxia.
METHODS: Patients with oropharyngeal cancer received (18)F-fluorodeoxyglucose (FDG) PET/CT, (18)F-fluorothymidine (FLT) PET/CT, and (61)Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) PET/CT. Images were co-registered and standardized uptake values (SUV) were calculated for all modalities. Voxel-based correlation was evaluated with Pearson's correlation coefficient in tumor regions. Additionally, sensitivity studies were performed to quantify the effects of image segmentation, registration, noise, and segmentation on R.
RESULTS: On average, FDG PET and FLT PET images were most highly correlated (R(FDG:FLT) = 0.76, range 0.53-0.85), while Cu-ATSM PET showed greater heterogeneity in correlation to other tracers (R(FDG:Cu-ATSM) = 0.64, range 0.51-0.79; R(FLT:Cu-ATSM) = 0.61, range 0.21-0.80). Of the tested parameters, correlation was most sensitive to image registration. Misregistration of one voxel lead to ΔR(FDG) = 0.25, ΔR(FLT) = 0.39, and ΔR(Cu-ATSM) = 0.27. Image noise and reconstruction also had quantitative effects on correlation. No significant quantitative differences were found between GTV, expanded GTV, or CTV regions.
CONCLUSIONS: Voxel-based correlation represents a first step into understanding spatial organization of tumor phenotype. These results have implications for radiotherapy target definition and provide a framework to test outcome prediction based on pretherapy distribution of phenotype.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23068711      PMCID: PMC3494460          DOI: 10.1016/j.radonc.2012.09.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  30 in total

1.  Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo.

Authors:  J R Grierson; A F Shields
Journal:  Nucl Med Biol       Date:  2000-02       Impact factor: 2.408

2.  Over-expression of facilitative glucose transporter genes in human cancer.

Authors:  T Yamamoto; Y Seino; H Fukumoto; G Koh; H Yano; N Inagaki; Y Yamada; K Inoue; T Manabe; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-16       Impact factor: 3.575

3.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Authors:  K S Chao; W R Bosch; S Mutic; J S Lewis; F Dehdashti; M A Mintun; J F Dempsey; C A Perez; J A Purdy; M J Welch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

4.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.

Authors:  Hubert Vesselle; John Grierson; Mark Muzi; Jeffrey M Pugsley; Rodney A Schmidt; Peter Rabinowitz; Lanell M Peterson; Eric Vallières; Douglas E Wood
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

5.  Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling.

Authors:  Stephen R Bowen; Albert J van der Kogel; Marianne Nordsmark; Søren M Bentzen; Robert Jeraj
Journal:  Nucl Med Biol       Date:  2011-05-05       Impact factor: 2.408

6.  Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen.

Authors:  Jean-François Daisne; Thierry Duprez; Birgit Weynand; Max Lonneux; Marc Hamoir; Hervé Reychler; Vincent Grégoire
Journal:  Radiology       Date:  2004-08-18       Impact factor: 11.105

7.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose.

Authors:  Abdelkarim S Allal; Daniel O Slosman; Tayeb Kebdani; Mohamed Allaoua; Willy Lehmann; Pavel Dulguerov
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-08-01       Impact factor: 7.038

8.  In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Authors:  Farrokh Dehdashti; Mark A Mintun; Jason S Lewis; Jeffrey Bradley; Ramaswamy Govindan; Richard Laforest; Michael J Welch; Barry A Siegel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

9.  [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Authors:  J G Rajendran; D C Wilson; E U Conrad; L M Peterson; J D Bruckner; J S Rasey; L K Chin; P D Hofstrand; J R Grierson; J F Eary; K A Krohn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-11       Impact factor: 9.236

10.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Authors:  Farrokh Dehdashti; Perry W Grigsby; Mark A Mintun; Jason S Lewis; Barry A Siegel; Michael J Welch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

View more
  18 in total

1.  Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

Authors:  Tyler J Bradshaw; Stephen Yip; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-28       Impact factor: 7.038

2.  In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.

Authors:  Catharina M L Zegers; Wouter van Elmpt; Bart Reymen; Aniek J G Even; Esther G C Troost; Michel C Ollers; Frank J P Hoebers; Ruud M A Houben; Jonas Eriksson; Albert D Windhorst; Felix M Mottaghy; Dirk De Ruysscher; Philippe Lambin
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.

Authors:  Peter Lin; Myo Min; Mark Lee; Lois Holloway; Dion Forstner; Victoria Bray; Allan Fowler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-21       Impact factor: 9.236

4.  Imaging and dosimetric errors in 4D PET/CT-guided radiotherapy from patient-specific respiratory patterns: a dynamic motion phantom end-to-end study.

Authors:  S R Bowen; M J Nyflot; C Herrmann; C M Groh; J Meyer; S D Wollenweber; C W Stearns; P E Kinahan; G A Sandison
Journal:  Phys Med Biol       Date:  2015-04-17       Impact factor: 3.609

5.  Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.

Authors:  Matthew J Nyflot; Tim J Kruser; Anne M Traynor; Deepak Khuntia; David T Yang; Gregory K Hartig; Timothy M McCulloch; Peggy A Wiederholt; Lindell R Gentry; Tien Hoang; Robert Jeraj; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-03       Impact factor: 7.038

Review 6.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-09-16       Impact factor: 10.057

8.  (18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer.

Authors:  Ang Gao; Shijiang Wang; Zheng Fu; Xindong Sun; Jinming Yu; Xue Meng
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 9.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.

Authors:  Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb
Journal:  Antioxid Redox Signal       Date:  2014-05-09       Impact factor: 8.401

10.  Parametric imaging of ¹⁸F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity.

Authors:  M Veronese; G Rizzo; E O Aboagye; A Bertoldo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.